AVTX Earnings Avalo Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–32 of 32
| Q2 2026 | 2026-06-30 | -0.83 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.98 | 2026-05-13 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -0.48 | 2026-03-23 | 10-K |
| FY 2025 | 2025-12-31 | -5.84 | 2026-03-23 | 10-K |
| Q3 2025 | 2025-09-30 | -2.19 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.92 | 2025-08-07 | 10-Q |
| Q1 2025 | 2025-03-31 | -1.25 | 2025-05-12 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 137.13 | 2025-03-20 | 10-K |
| FY 2024 | 2024-12-31 | -20.91 | 2025-03-20 | 10-K |
| Q3 2024 | 2024-09-30 | -2.83 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -14.07 | 2024-08-12 | 10-Q |
| Q1 2024 | 2024-03-31 | -141.14 | 2024-05-13 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 257.98 | 2024-03-29 | 10-K |
| FY 2023 | 2023-12-31 | -113.58 | 2024-03-29 | 10-K |
| Q3 2023 | 2023-09-30 | -26.83 | 2023-11-09 | 10-Q |
| Q2 2023 | 2023-06-30 | -140.73 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -204.00 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -215.50 | 2023-03-29 | 10-K |
| FY 2022 | 2022-12-31 | -1063.00 | 2023-03-29 | 10-K |
| Q3 2022 | 2022-09-30 | 85.00 | — | — |
| Q2 2022 | 2022-06-30 | -345.00 | — | — |
| Q1 2022 | 2022-03-31 | -587.50 | — | — |
| FY 2018 | 2018-12-31 | -300.00 | 2019-03-18 | 10-K |
| Q3 2018 | 2018-09-30 | -177.50 | 2018-11-13 | 10-Q |
| Q4 2017 | 2017-12-31 | -27.50 | 2018-04-02 | 10-K |
| FY 2017 | 2017-12-31 | 105.00 | 2018-04-02 | 10-K |
| Q3 2017 | 2017-09-30 | 130.00 | 2017-11-07 | 10-Q |
| Q2 2017 | 2017-06-30 | -35.00 | — | — |
| Q1 2017 | 2017-03-31 | -47.50 | — | — |
| FY 2016 | 2016-12-31 | -467.50 | — | — |
| Q3 2016 | 2016-09-30 | -175.00 | — | — |
| FY 2015 | 2015-12-31 | -1177.50 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.